This whitepaper provides actionable advice for Biotech business development leaders on how to get ready for a partnering deal.

This whitepaper evaluates the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF, how to avoid writing too many and unnecessary Note-to-Files (NTFs), and tips on becoming inspection ready and staying that way.

This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.

In this whitepaper, explore the nuances of valuation, its framework and the processes for getting it right.

This whitepaper gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.

This whitepaper shares the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered.

In this whitepaper, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores the current oncology landscape and offers insightful perspective on trends, pipeline by indication, dealmaking, and the top ten oncology companies and the drugs they’re developing.

This whitepaper is based on our web panel discussion on how to successfully move a life science organization from founding to exit.

This whitepaper explains the security risks associated with the proliferation of SharePoint sites, the biggest challenges in developing extranets, and the most secure ways to share proprietary, highly confidential documents with third parties within a SharePoint environment.

This white paper provides several topics to consider before investing in, planning and executing a business development initiative and the challenges presented by organizational structure and the importance of goal setting, flexibility and story-telling in a business context.

This whitepaper breaks down the six major stakeholder categories relevant to most life science companies, and shares key strategies for closing the knowledge gap between founders and their market success.

In this whitepaper, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, what are the indications being pursued, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.